UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 98,725 Shares of Moderna, Inc. $MRNA

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 6.1% in the second quarter, Holdings Channel reports. The firm owned 1,521,849 shares of the company’s stock after selling 98,725 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Moderna were worth $106,575,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in MRNA. Louisiana State Employees Retirement System bought a new stake in Moderna during the 1st quarter valued at $899,000. Merck & Co. Inc. purchased a new stake in shares of Moderna in the 2nd quarter worth $161,642,545. Bank of New York Mellon Corp bought a new position in shares of Moderna during the 2nd quarter worth $119,168,000. Contravisory Investment Management Inc. increased its stake in shares of Moderna by 1,387.6% during the second quarter. Contravisory Investment Management Inc. now owns 24,218 shares of the company’s stock valued at $1,696,000 after buying an additional 22,590 shares during the period. Finally, Lingotto Investment Management LLP increased its stake in shares of Moderna by 33.7% during the fourth quarter. Lingotto Investment Management LLP now owns 498,693 shares of the company’s stock valued at $14,706,000 after buying an additional 125,598 shares during the period. 75.33% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Moderna news, President Stephen Hoge sold 53,336 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $51.37, for a total value of $2,739,870.32. Following the completion of the sale, the president directly owned 1,483,848 shares in the company, valued at $76,225,271.76. This trade represents a 3.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Thyme Klinger sold 3,471 shares of Moderna stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $50.00, for a total transaction of $173,550.00. Following the completion of the transaction, the insider directly owned 67,468 shares in the company, valued at $3,373,400. This represents a 4.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 10.80% of the stock is owned by insiders.

Trending Headlines about Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Positive late-stage results from Moderna and Merck’s personalized melanoma vaccine remain the primary catalyst. The data reinforced expectations that Moderna can expand beyond COVID-19 vaccines into cancer immunotherapy and potentially create a significant long-term revenue stream. Moderna Stock More Than Doubled in August. Is the Stock a Buy, a Hold, or a Sell?
• Positive Sentiment: Options activity was notably bullish, with investors purchasing 106,605 call contracts—about 35% above typical volume. The activity suggests increased speculative interest in further gains, although options positioning can also amplify volatility.
• Positive Sentiment: Moderna’s updated COVID-19 vaccine approvals and the company’s recent momentum have helped restore investor confidence in its commercial and regulatory execution. Shares more than doubled during August, making the stock one of the market’s strongest performers. Moderna (MRNA) Soars 156% in August — Here’s What Propelled The Rally
• Neutral Sentiment: Moderna will present at the Morgan Stanley Global Healthcare Conference on September 14 and the Bernstein Healthcare Forum on September 23. These events could provide updates on the oncology pipeline, vaccine demand and the path to profitability, but no new financial information was announced. Moderna to Present at Upcoming Conferences in September 2026
• Negative Sentiment: GSK advanced its competing mRNA influenza vaccine into a Phase III trial, increasing future competitive pressure shortly after Moderna received approval for the first seasonal flu mRNA vaccine. Investors appear to be treating the threat as manageable for now, with greater emphasis on Moderna’s cancer program. GSK hopes to take on Moderna as it moves mRNA flu vaccine to Phase III trial
• Negative Sentiment: Brookline Capital Markets modestly reduced its FY2029 and FY2030 EPS estimates, while maintaining a Buy rating. The cuts signal limited near-term financial visibility as Moderna remains loss-making and analysts expect a full-year loss.

Moderna Price Performance

Shares of MRNA stock opened at $154.27 on Wednesday. The stock’s 50-day moving average is $80.59 and its 200 day moving average is $61.34. Moderna, Inc. has a 1-year low of $22.28 and a 1-year high of $176.66. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.18. The company has a market cap of $61.59 billion, a P/E ratio of -19.31 and a beta of 1.09.

Moderna (NASDAQ:MRNA) last announced its earnings results on Friday, July 31st. The company reported ($1.97) EPS for the quarter, topping analysts’ consensus estimates of ($2.03) by $0.06. The business had revenue of $145.00 million during the quarter, compared to the consensus estimate of $102.93 million. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The firm’s revenue was up 2.1% on a year-over-year basis. During the same period in the previous year, the company posted ($2.13) earnings per share. Research analysts predict that Moderna, Inc. will post -6.11 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on MRNA. Loop Capital set a $135.00 price objective on shares of Moderna in a research note on Wednesday, August 19th. JPMorgan Chase & Co. raised their target price on shares of Moderna from $40.00 to $77.00 and gave the company an “underweight” rating in a research report on Friday, August 21st. Morgan Stanley boosted their price target on shares of Moderna from $39.00 to $89.00 and gave the company an “equal weight” rating in a report on Thursday, August 20th. Bank of America raised shares of Moderna from an “underperform” rating to a “neutral” rating in a research report on Wednesday, August 19th. Finally, Wolfe Research raised shares of Moderna from an “underperform” rating to a “peer perform” rating in a report on Tuesday, August 25th. Seven analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Moderna has an average rating of “Hold” and an average target price of $80.53.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.